Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2015-09-01 Regulatory Filings
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated September 1, 2015, from ABIVAX announcing its eligibility for the PEA-PME (a French equity savings plan for SMEs). This announcement relates to the company's structure and compliance with specific financial regulations/designations, but it is not a standard periodic financial report (like 10-K or IR), an earnings release (ER), a management discussion (MDA), or a capital raising event (CAP). It is a specific corporate announcement concerning regulatory status/eligibility. Since it doesn't fit perfectly into the defined categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Major Shareholding (MRQ), and it is a specific regulatory/corporate status update, the most appropriate fallback category is Regulatory Filings (RNS), as it is a general regulatory announcement that doesn't fit the more specific corporate action codes.
2015-09-01 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is a very short announcement (2946 characters) titled "ABIVAX to report first-half 2015 results". It explicitly states that the company 'will publish its financial results for the first half of 2015 on September 29, 2015'. This structure—announcing the future release date of a report rather than containing the full report itself—fits the definition of a Report Publication Announcement (RPA). It is not the Interim Report (IR) itself, nor is it an Earnings Release (ER) which typically contains the actual results highlights. The 'MENU VS MEAL' rule strongly suggests RPA in this context.
2015-09-01 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is very short (2760 characters) and its primary purpose is to announce the future date (September 29, 2015) when the company's financial results for the period ending June 30, 2015, will be published. It explicitly states, "ABIVAX... annonce la date de la publication de ses résultats au 30 juin 2015, qui sera le 29 septembre 2015, après bourse." According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report will be published or attached classifies as a Report Publication Announcement (RPA). It is not the actual Interim Report (IR) or Earnings Release (ER) itself.
2015-09-01 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.